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CASE REPORT
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Abstract 
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the 
sense of smell, resulting in a significant impairment in quality of life. The medical treatments currently available may 
improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report 
the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab.
Case presentation: The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatopha-
goides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuc-
cessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, 
treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly 
in complete recovery of the smell loss after 4 months of treatment and still persisting.
Conclusion: In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and 
affected by CRSwNP was associated with an improvement of anosmia. That finding may be explained by a reduction 
of the nasal obstruction by nasal polyps.
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Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is 
characterized by the occurrence for more than 12 weeks 
of symptoms as nasal discharge, stuffiness, facial pres-
sure or pain, dysfunction or loss of the sense of smell, 
and cough from post-nasal drip [1]. Among such symp-
toms, smell loss is strongly associated with impairment 
in quality of life [2]. The cause of the olfactory loss in 
patients with CRSwNP is acknowledged in inflamma-
tion within the olfactory cleft; the degree of dysfunc-
tion is associated with the grade of inflammation and 
the altered turnover of the olfactory sensory neurons 
caused by chronic inflammation. The treatment available 
thus far may significantly improve the olfactory function 
in patients with CRSwNP, but the improvement is only 
temporary, and further treatment aimed at persistent 
elimination of inflammation and promotion of a nor-
mal turnover of the olfactory epithelium are warranted 
[3]. Sinonasal tissue eosinophilia is quite common in 
CRSwNP, defining the endotype of eosinophilic CRSwNP 
[4]. Based on the crucial importance of interleukin 5 (IL-
5) in promoting eosinophils development and survival, 
the anti-IL-5 monoclonal antibody mepolizumab is cur-
rently evaluated, along with other biologic agents [5], as 
a treatment for CRSwNP. Anti-IL5 therapy proved ben-
eficial in the treatment of recalcitrant nasal polyposis in 
selected populations and significantly reduced smell loss 
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starting from 9  weeks of treatment compared with pla-
cebo [6]. However, no patient achieving complete recov-
ery of smell sense was reported. We describe the case of 
a patient allergic to dust mites with severe asthma and 
CRSwNP who had a smell loss unresponsive to any ther-
apy. The patient underwent treatment with mepolizumab 
for severe asthma and achieved, along with asthma con-
trol, complete sense of smell recovery after 4 months of 
treatment.
Case presentation
The patient was a 62-year-old female suffering since 
adolescence from mite-induced asthma, as assessed by 
positive in  vitro testing to Dermatophagoides pteronys-
sinus and Dermatophagoides farinae, with development 
in latest years of severe asthma not controlled by stand-
ard drug treatment. The patient fulfilled the admission 
criteria to mepolizumab treatment, as defined by severe 
asthma from ≥ 12  months despite high-dose inhaled 
corticosteroids (ICS) plus additional controller(s) treat-
ment, ≥ 2 exacerbations (requiring systemic corticos-
teroid and/or ED visit and/or hospitalization in prior 
12 months) and blood eosinophil ≥ 150 cells/µl at visit 1 
or historically ≥ 300 cells/µl [7]. Lung function measure-
ment by plethysmography showed a forced expiratory 
volume in 1 s (FEV1) of 64% and significant reversibility 
to 80% following inhalation of salbutamol 400 µg. From 
1998, the patient also suffered concomitant CRSwNP. 
The disease state was investigated by computed tomog-
raphy (CT), which showed a picture of pansinusitis with 
almost complete obliteration of all the paranasal cavi-
ties, with erosive reabsorption phenomena associated 
to the presence of numerous polypoid formations in 
the ethmoidal cells, extending to the nasopharynx. The 
patient was previously treated with many drugs, includ-
ing oral and injective corticosteroids, with some benefit 
on nasal discharge, stuffiness, facial pressure, and cough 
but no effect on the loss of the sense of smell. Starting 
from March 2018, mepolizumab treatment by 100 mg at 
monthly intervals was performed, that resulted in good 
clinical control of both asthma and CRSwNP, a complete 
recovery of the smell loss occurring in the latter after 
4  months of treatment and persisting. Figures  1 and 2 
show the results of paranasal sinuses CT before (T0) and 
after (T1) mepolizumab treatment in axial and coronal 
projection, with evident improvement after treatment.
Discussion and conclusion
The introduction of biologic therapies for severe asthma 
was a milestone in the management of this challenging 
condition. Of interest, biologic agents were found to be 
successful in several other disorders, as demonstrated 
for the monoclonal anti-IgE antibody omalizumab, 
which is effective on a large array of pathologies, even 
not IgE-mediated. This is true for chronic spontaneous 
urticaria, for which omalizumab treatment was licensed, 
and also for CRSwNP, though for such disease omali-
zumab therapy is off-label [8]. The anti-IL-5 monoclonal 
antibody mepolizumab is indicated in the severe eosino-
philic asthma phenotype. In a cohort of 670 patients with 
severe asthma candidate for biologic treatment, 20% were 
eligible for mepolizumab [7], and the studies available 
thus far demonstrated the effectiveness of this treatment.
Fig. 1 Axial CT comparison before and after therapy: paranasal sinuses CT in axial projection at t0: bilateral engagement of maxillary sinuses (a), 
and at T1 CT: clear improvement in the maxillary sinuses which show only slight mucosal hypertrophy (b)
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Similarly to asthma, also CRSwNP comprises an eosin-
ophilic endotype, and the meta-analysis of five studies 
(four randomized control trials (RCT), one case–control 
and two case series) investigating the treatment outcome, 
demonstrated a standard mean difference of improve-
ment in nasal polyposis significantly higher for both 
omalizumab and mepolizumab compared with placebo. 
In  particular, anti-IL5  treatment  resulted in a reduction 
in  nasal  polyp score. These data suggested the authors 
conclude that biologic  therapies may prove beneficial in 
the  treatment  of recalcitrant  nasal polyposis  in selected 
populations [5]. To achieve complete recovery of smell 
loss was not considered thus far, due to the unsatisfactory 
results obtained by all previous treatments, as a credible 
need to meet. In the case reported, the treatment with 
mepolizumab was associated with a marked improve-
ment in the olfactory capacity of the patient. Also, the 
other symptoms of CRS regressed, even if, unfortunately, 
we did not objectivize it by assessing a clinical score as 
the 22 items Sino-Nasal Score (SNOT-22). Although the 
results obtained in our patient were promising, it should 
be remembered that the patient was allergic to Der-
matophagoides and therefore it would not be correct to 
extend our observation to patients allergic to other types 
of allergens.
The case we have observed proposes to perform spe-
cific studies on patients with CRSwNP who have devel-
oped anosmia to verify the ability of mepolizumab to 
work on a symptom significantly impairing the patient’s 
quality of life.
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Fig. 2 Coronal CT comparison before and after therapy: paranasal sinuses in coronal projection at T0: engagement of both maxillary sinuses, nasal 
cavities and ethmoid (a), and at T1: visible improvement of both maxillary sinuses, with almost complete patency of the nasal cavities and the 
ethmoid (b)
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